WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals, Inc. (ALXN) said Wednesday that the primary composite endpoint its Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection in living-donor kidney transplant recipients requiring desensitization did not reach statistical significance.
The primary composite endpoint was defined as the occurrence of biopsy-proven AMR, graft loss, patient death, or loss to follow-up at Week 9 post-transplant,
While the primary composite endpoint rate in the eculizumab arm was as expected from earlier studies with eculizumab, the rate in the control arm was lower than was expected, the company said.
Copyright RTT News/dpa-AFX